111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.

E. Bombardieri, A. Chiti, F. Crippa, E. Seregni, I. Cataldo, L. Maffioli, E. Soresi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-one patients with small cell lung cancer (SCLC) were investigated with 111in-octreotide (111-In-OCT) scintigraphs, 5 hours after the i.v. injection of 111 MBq of the radiotracer. Whole-body and planar scintigraphy as well as SPECT of the thorax were required. The scintigraphic results were compared to those of other conventional diagnostic procedures used for the staging and follow-up of SCLC patients. 111In-OCT detected 86% (48/56) of the lesions already known at the time of scintigraphy, being positive for all 20 SCLC lesions and negative for one lung adenocarcinoma. 111In-OCT showed a high sensitivity for mediastinal metastases (94%) and good sensitivity for bone (75%) and abdominal lymph node metastases (71%). It did not detect 2 liver metastases but revealed 5 unknown lesions which were then confirmed by other diagnostic examinations. 111In-OCT was also effective in patients with low levels of NSE. Three patients received cold octreotide for seven days to investigate whether this treatment might affect SCLC imaging. Scans were performed before and after treatment. The 111In-OCT uptake increased in the cancer lesions while the fixation in normal tissues decreased, demonstrating enhancement of SCLC imaging following cold octreotide administration.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalQuarterly Journal of Nuclear Medicine
Volume39
Issue number4 Suppl 1
Publication statusPublished - Dec 1995

Fingerprint

Small Cell Lung Carcinoma
Radionuclide Imaging
Octreotide
Neoplasm Metastasis
Single-Photon Emission-Computed Tomography
Thorax
Lymph Nodes
SDZ 215-811
Bone and Bones
Injections
Liver
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer. / Bombardieri, E.; Chiti, A.; Crippa, F.; Seregni, E.; Cataldo, I.; Maffioli, L.; Soresi, E.

In: Quarterly Journal of Nuclear Medicine, Vol. 39, No. 4 Suppl 1, 12.1995, p. 104-107.

Research output: Contribution to journalArticle

Bombardieri, E, Chiti, A, Crippa, F, Seregni, E, Cataldo, I, Maffioli, L & Soresi, E 1995, '111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.', Quarterly Journal of Nuclear Medicine, vol. 39, no. 4 Suppl 1, pp. 104-107.
Bombardieri, E. ; Chiti, A. ; Crippa, F. ; Seregni, E. ; Cataldo, I. ; Maffioli, L. ; Soresi, E. / 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer. In: Quarterly Journal of Nuclear Medicine. 1995 ; Vol. 39, No. 4 Suppl 1. pp. 104-107.
@article{3f152128c564470e82de4e1a6e83682a,
title = "111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.",
abstract = "Twenty-one patients with small cell lung cancer (SCLC) were investigated with 111in-octreotide (111-In-OCT) scintigraphs, 5 hours after the i.v. injection of 111 MBq of the radiotracer. Whole-body and planar scintigraphy as well as SPECT of the thorax were required. The scintigraphic results were compared to those of other conventional diagnostic procedures used for the staging and follow-up of SCLC patients. 111In-OCT detected 86{\%} (48/56) of the lesions already known at the time of scintigraphy, being positive for all 20 SCLC lesions and negative for one lung adenocarcinoma. 111In-OCT showed a high sensitivity for mediastinal metastases (94{\%}) and good sensitivity for bone (75{\%}) and abdominal lymph node metastases (71{\%}). It did not detect 2 liver metastases but revealed 5 unknown lesions which were then confirmed by other diagnostic examinations. 111In-OCT was also effective in patients with low levels of NSE. Three patients received cold octreotide for seven days to investigate whether this treatment might affect SCLC imaging. Scans were performed before and after treatment. The 111In-OCT uptake increased in the cancer lesions while the fixation in normal tissues decreased, demonstrating enhancement of SCLC imaging following cold octreotide administration.",
author = "E. Bombardieri and A. Chiti and F. Crippa and E. Seregni and I. Cataldo and L. Maffioli and E. Soresi",
year = "1995",
month = "12",
language = "English",
volume = "39",
pages = "104--107",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "4 Suppl 1",

}

TY - JOUR

T1 - 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.

AU - Bombardieri, E.

AU - Chiti, A.

AU - Crippa, F.

AU - Seregni, E.

AU - Cataldo, I.

AU - Maffioli, L.

AU - Soresi, E.

PY - 1995/12

Y1 - 1995/12

N2 - Twenty-one patients with small cell lung cancer (SCLC) were investigated with 111in-octreotide (111-In-OCT) scintigraphs, 5 hours after the i.v. injection of 111 MBq of the radiotracer. Whole-body and planar scintigraphy as well as SPECT of the thorax were required. The scintigraphic results were compared to those of other conventional diagnostic procedures used for the staging and follow-up of SCLC patients. 111In-OCT detected 86% (48/56) of the lesions already known at the time of scintigraphy, being positive for all 20 SCLC lesions and negative for one lung adenocarcinoma. 111In-OCT showed a high sensitivity for mediastinal metastases (94%) and good sensitivity for bone (75%) and abdominal lymph node metastases (71%). It did not detect 2 liver metastases but revealed 5 unknown lesions which were then confirmed by other diagnostic examinations. 111In-OCT was also effective in patients with low levels of NSE. Three patients received cold octreotide for seven days to investigate whether this treatment might affect SCLC imaging. Scans were performed before and after treatment. The 111In-OCT uptake increased in the cancer lesions while the fixation in normal tissues decreased, demonstrating enhancement of SCLC imaging following cold octreotide administration.

AB - Twenty-one patients with small cell lung cancer (SCLC) were investigated with 111in-octreotide (111-In-OCT) scintigraphs, 5 hours after the i.v. injection of 111 MBq of the radiotracer. Whole-body and planar scintigraphy as well as SPECT of the thorax were required. The scintigraphic results were compared to those of other conventional diagnostic procedures used for the staging and follow-up of SCLC patients. 111In-OCT detected 86% (48/56) of the lesions already known at the time of scintigraphy, being positive for all 20 SCLC lesions and negative for one lung adenocarcinoma. 111In-OCT showed a high sensitivity for mediastinal metastases (94%) and good sensitivity for bone (75%) and abdominal lymph node metastases (71%). It did not detect 2 liver metastases but revealed 5 unknown lesions which were then confirmed by other diagnostic examinations. 111In-OCT was also effective in patients with low levels of NSE. Three patients received cold octreotide for seven days to investigate whether this treatment might affect SCLC imaging. Scans were performed before and after treatment. The 111In-OCT uptake increased in the cancer lesions while the fixation in normal tissues decreased, demonstrating enhancement of SCLC imaging following cold octreotide administration.

UR - http://www.scopus.com/inward/record.url?scp=0029421764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029421764&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 104

EP - 107

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 4 Suppl 1

ER -